Haemonetics HAE
$120.16 −$0.21 (-0.17%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $120.16 0.00%
Open$120.37
Prev close$120.37
Day range$119.68 – $122.34
Volume383.0K
Market cap$5.47B
P/E (TTM)53.2
Dividend yield–
Fundamentals
Latest reported quarter: Q2, ended Sep 2026
Revenue$357.76M+9.3% YoY
Operating profit$75.12M+12.0% YoY
Net profit$46.31M+19.7% YoY
Diluted EPS$1.00+23.5% YoY
Free cash flow$113.33M+6.6% YoY
Operating cash flow$128.10M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin59.6%
Operating margin18.3%
Net margin7.5%
Return on equity11.9%
Return on assets4.3%
Return on invested capital6.3%
Current ratio2.84
Liabilities / assets62.7%
Cash & investments$260.71M
Total debt$1.12B
Net cash (debt)-$863.05M
Free cash flow / sales21.6%
Where the revenue comes from
Quarter 2027/Q2
By business line
Income statement
| Line item | 2027 Q2 | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $357.76M | $339.38M | $1.33B | $346.35M | $338.97M |
| Total Operating Revenue | $357.76M | $339.38M | $1.33B | $346.35M | $338.97M |
| Cost of Revenue | $136.85M | $136.58M | $546.44M | $148.14M | $136.58M |
| Gross Profit | $220.91M | $202.80M | $787.59M | $198.21M | $202.39M |
| Operating Expense | $145.79M | $145.35M | $546.19M | $145.87M | $134.27M |
| Selling and Admin Expenses | $118.36M | $118.94M | $442.42M | $120.93M | $109.15M |
| Research & Development | $17.03M | $16.20M | $59.77M | $14.45M | $14.19M |
| Depreciation & Amortization & Depletion | $10.40M | $10.20M | $44.00M | $10.49M | $10.93M |
| -Depreciation & Amortization | $10.40M | $10.20M | $44.00M | $10.49M | $10.93M |
| Operating Profit | $75.12M | $57.46M | $241.40M | $52.34M | $68.11M |
| Net Non-Operating Interest Income (Expense) | -$12.26M | -$9.88M | -$28.70M | -$5.37M | -$7.42M |
| Non-Operating Interest Expense | $12.26M | $9.88M | $28.70M | $5.37M | $7.42M |
| Special Income (Charges) | $0.00 | – | -$84.67M | -$75.37M | -$716,000.00 |
| -Less:Impairment of Capital Assets | $0.00 | – | $86.55M | $77.25M | $716,000.00 |
| Pretax Profit | $62.86M | $47.57M | $128.03M | -$28.40M | $59.98M |
| Tax | $16.55M | $14.56M | $30.72M | -$8.25M | $15.24M |
| Net Profit | $46.31M | $33.01M | $97.31M | -$20.15M | $44.74M |
| Profit from Continuing Operations | $46.31M | $33.01M | $97.31M | -$20.15M | $44.74M |
| Net Income to Parent Company | $46.31M | $33.01M | $97.31M | -$20.15M | $44.74M |
| Net Income to Common Stockholders | $46.31M | $33.01M | $97.31M | -$20.15M | $44.74M |
| Basic EPS | $1.02 | $0.73 | $2.06 | -$0.44 | $0.96 |
| Diluted EPS | $1.00 | $0.72 | $2.05 | -$0.44 | $0.95 |
| Other Income (Expense) | – | – | -$84.67M | -$75.37M | -$716,000.00 |
| -Less:Restructuring and Mergern & Acquisition | – | – | -$1.88M | – | – |
Balance sheet
| Line item | 2027 Q2 | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 |
|---|---|---|---|---|---|
| Total Assets | $2.41B | $2.37B | $2.40B | $2.40B | $2.49B |
| Total Current Assets | $855.53M | $810.83M | $834.88M | $834.88M | $943.67M |
| Cash and Cash Equivalents & Short-Term Investments | $260.71M | $223.38M | $245.44M | $245.44M | $363.37M |
| -Cash and Cash Equivalents | $260.71M | $223.38M | $245.44M | $245.44M | $363.37M |
| Receivables | $224.95M | $216.07M | $216.86M | $216.86M | $195.71M |
| -Accounts Receivable | $224.95M | $216.07M | $216.86M | $216.86M | $195.71M |
| Inventory | $305.01M | $306.74M | $306.37M | $306.37M | $321.19M |
| Other Current Assets | $64.86M | $64.64M | $66.21M | $66.21M | $63.42M |
| Total Non-Current Assets | $1.56B | $1.55B | $1.56B | $1.56B | $1.55B |
| Net PPE | $307.92M | $303.78M | $305.76M | $305.76M | $297.23M |
| -Gross PPE | $873.32M | $854.27M | $841.83M | $841.83M | $836.81M |
| -Accumulated Depreciation | -$565.40M | -$550.49M | -$536.07M | -$536.07M | -$539.58M |
| Goodwill and Other Intangible Assets | $1.08B | $1.09B | $1.10B | $1.10B | $1.03B |
| -Goodwill | $657.10M | $656.88M | $656.37M | $656.37M | $606.83M |
| -Other Intangible Assets | $426.36M | $434.51M | $447.66M | $447.66M | $419.73M |
| Non-Current Deferred Assets | $9.35M | $9.43M | $9.52M | $9.52M | $7.33M |
| Other Non-Current Assets | $154.34M | $149.96M | $141.74M | $141.74M | $216.09M |
| Total Liabilities | $1.51B | $1.53B | $1.60B | $1.60B | $1.58B |
| Total Current Liabilities | $300.84M | $263.24M | $282.60M | $282.60M | $539.87M |
| Payables | $71.64M | $56.34M | $51.06M | $51.06M | $48.69M |
| -Accounts Payable | $71.64M | $56.34M | $51.06M | $51.06M | $48.69M |
| Current Accrued Expenses | $54.42M | $38.15M | $68.19M | $68.19M | $52.10M |
| Short-Term Debt and Capital Lease Obligation | $9.64M | $4.96M | $5.02M | $5.02M | $304.75M |
| -Current Debt | $9.64M | $4.96M | $5.02M | $5.02M | $304.75M |
| Other Current Liabilities | $165.13M | $163.80M | $116.03M | $116.03M | $134.33M |
| Total Non-Current Liabilities | $1.21B | $1.27B | $1.32B | $1.32B | $1.04B |
| Long Term Debt and Capital Lease Obligation | $1.11B | $1.17B | $1.22B | $1.22B | $919.99M |
| -Long Term Debt | $1.11B | $1.17B | $1.22B | $1.22B | $919.99M |
| Non-Current Deferred Liabilities | $41.82M | $38.69M | $38.05M | $38.05M | $55.98M |
| Other Non-Current Liabilities | $55.33M | $57.17M | $59.39M | $59.39M | $63.61M |
| Total Equity | $898.50M | $837.10M | $796.32M | $796.32M | $911.45M |
| Stockholders' Equity | $898.50M | $837.10M | $796.32M | $796.32M | $911.45M |
| Capital Stock | $455,000.00 | $455,000.00 | $453,000.00 | $453,000.00 | $468,000.00 |
| -Common Stock | $455,000.00 | $455,000.00 | $453,000.00 | $453,000.00 | $468,000.00 |
| Additional Paid-In Capital | $579.80M | $566.76M | $554.14M | $554.14M | $564.50M |
| Retained Earnings | $356.96M | $311.52M | $279.34M | $279.34M | $381.09M |
| Gains/Losses Not Affecting Retained Earnings | -$38.72M | -$41.63M | -$37.61M | -$37.61M | -$34.61M |
| Current Deferred Liabilities | – | – | $42.31M | $42.31M | – |
Cash flow
| Line item | 2027 Q2 | 2027 Q1 | 2026 ANNUAL | 2026 Q4 | 2026 Q3 |
|---|---|---|---|---|---|
| Operating Cash Flow | $128.10M | $52.32M | $293.22M | $70.94M | $93.56M |
| Net cash flow from continuing operations | $128.10M | $52.32M | $293.22M | $70.94M | $93.56M |
| Net Income from Continuing Operations | $46.31M | $33.01M | $97.31M | -$20.15M | $44.74M |
| Depreciation & Depletion & Amortization | $27.76M | $27.11M | $111.72M | $27.32M | $27.39M |
| Deferred Tax | $2.57M | $668,000.00 | -$714,000.00 | $5.30M | -$2.06M |
| Other Non-Cash Items | $3.16M | $2.23M | $3.94M | -$6.63M | $3.71M |
| Change in Working Capital | $38.08M | -$20.00M | -$12.93M | $4.66M | $11.81M |
| -Change in Receivables | -$8.36M | $297,000.00 | -$14.88M | -$22.24M | $11.06M |
| -Change in Inventory | $1.98M | -$1.00M | $47.36M | $8.46M | $13.84M |
| -Change in Prepaid Assets | -$3.67M | $6.10M | -$4.53M | -$5.89M | -$1.78M |
| -Change in Payables and Accrued Expense | $53.63M | -$12.62M | -$16.57M | $20.32M | -$6.70M |
| -Change In Other Working Capital | -$5.49M | -$12.78M | -$24.30M | $4.00M | -$4.61M |
| Net cash flow from investing | -$24.29M | -$22.23M | -$179.55M | -$86.61M | -$29.47M |
| Net Cash Flow from Continuing Investing Activities | -$24.29M | -$22.23M | -$179.55M | -$86.61M | -$29.47M |
| Capital Expenditure | -$14.77M | -$7.91M | -$32.78M | -$17.66M | -$6.35M |
| Net PPE Purchase and Sale | $576,000.00 | $237,000.00 | $1.38M | $526,000.00 | $432,000.00 |
| Net Other Investing Changes | -$19.09M | -$5.57M | -$51.89M | $26.77M | -$23.55M |
| Financing Cash Flow | -$67.61M | -$51.53M | -$178.46M | -$101.50M | $2.03M |
| Net Cash Flow from Continuing Financing Activities | -$67.61M | -$51.53M | -$178.46M | -$101.50M | $2.03M |
| Net Issuance Payments Of Debt | -$51.56M | -$51.56M | -$6.25M | -$1.56M | -$1.56M |
| Proceeds from Stock Option Exercised | $1.56M | $49,000.00 | $2.89M | $76,000.00 | $3.61M |
| Net Other Financing Charges | -$17.61M | -$14,000.00 | -$102,000.00 | -$13,000.00 | -$14,000.00 |
| Ending Cash Balance | $260.71M | $223.38M | $245.44M | $245.44M | $363.37M |
| Net Change in Cash | $36.20M | -$21.44M | -$64.79M | -$117.17M | $66.13M |
| Beginning Cash Balance | $223.38M | $245.44M | $306.76M | $363.37M | $296.43M |
| Effect of Exchange Rate Changes | $1.13M | -$617,000.00 | $3.46M | -$756,000.00 | $810,000.00 |
| Free Cash Flow | $113.33M | $44.42M | $260.44M | $53.28M | $87.22M |
| Net Investment Purchase and Sale | – | -$9.00M | -$36.07M | – | – |
| Gain/Loss from Continuing Operations | – | – | -$26.47M | -$25.94M | -$218,000.00 |
| Net Business Purchase and Sale | – | – | -$60.18M | -$60.18M | $0.00 |
| Net Common Stock Issuance | – | – | -$175.00M | -$100.00M | $0.00 |
No comments yet — be the first to weigh in on HAE.
Sign in to join the discussion.